Azathioprine immunosuppression and disease modification in Parkinson's disease (AZA-PD): a randomised double-blind placebo-controlled phase II trial protocol. (2020)

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1136/bmjopen-2020-040527

PubMed Identifier: 33234645

Publication URI: http://europepmc.org/abstract/MED/33234645

Type: Journal Article/Review

Volume: 10

Parent Publication: BMJ open

Issue: 11

ISSN: 2044-6055